Revenio Group Corporation: Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act
Revenio Group Corporation: Notification of change in holdings according to Chapter 9, Section 10 of the Finnish Securities Market Act
Revenio Group Corporation | Stock Exchange Release | October 20, 2026 at 09:00:00 EEST
Revenio Group Corporation has received the following notification pursuant to Chapter 9, section 5 of the Securities Markets Act (”SMA”), according to which William Demant Invest A/S voting rights in Revenio Group exceeded 25 percent on October 19, 2026.
Total position of William Demant Invest A/S according to the notification:
| % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both in % | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 25.51% | 25.51% | 42,096,274 | |
| Position of previous notification (if applicable) | 20.03% | 20.03% |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights:
| Class/type of shares, ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009010912 | 10,737,252 | - | 25.51% | - |
| SUBTOTAL A | 10,737,252 | 25.51% | ||
For further information, please contact
CFO Jukka Kainulainen
+358 9 8775 1150
ir@revenio.fi
Distribution
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.reveniogroup.fi/en
Revenio Group in brief
Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio’s solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix.
In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. In 2025, the Group’s pro forma net sales totaled EUR 252.8 million, with a pro forma adjusted EBITDA of EUR 45.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.